LEXON
13.4.2021 09:32:11 CEST | Business Wire | Press release
Lexon today announced that it has received 6 Red Dot Awards for its outstanding product design quality in multiple categories, setting a new company record for the number of awards won in a single competition. Sister company MyKronoz also takes home a Red Dot Award for its MyScale , a smart and design body scale with a large and intuitive color display.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005520/en/
This announcement comes only a few weeks after Lexon’s best-selling Oblio was honored with two prestigious international prizes - a TIME Best Invention Award and a CES Innovation Award - confirming the French brand’s continued leadership in innovative product design, with a total of more than 200 awards received since its creation in 1991.
“2021 marks the 30th anniversary of Lexon, so this exceptional recognition comes at a perfect timing. We couldn’t be happier to celebrate this milestone with such paramount achievement which proves our consistent ability to create objects that combine aesthetics and function, but most importantly, that are part of our daily lives.
2021 is also synonymous with the global crisis, one that inevitably led us to adapt our business to new realities, to rethink our products portfolio and to focus even more on designing solutions that truly meet our changing environments, whether it’s for the home, the work or the new mobility.
Today, these distinctions not only celebrate our resilience, they also validate the quality of the experience we strive to bring to our customers in all circumstances,” says Boris Brault, Lexon’s CEO.
Since its acquisition by BOW Group in 2018, Lexon has experienced significant online growth and staggering expansion in the US where the brand is today listed among the most prominent retailers including Target, Nordstrom, Neiman Marcus, Best Buy and MoMA Design Store. In the coming weeks, Lexon will pursue its international development by completing the takeover of its long-term Chinese Master License who has built the brand domestically for the past 10 years, opening more than 80 retail stores, developing online sales on JD.com and Taobao, as well as growing profitable B2B activities.
The successful integration of Lexon among BOW Group has created highly valuable synergies with sister company MyKronoz, in terms of product design, R&D capabilities, sales channels and digitalization. BOW Group has thereby proven its ability to acquire external companies within its manufacturing, selling and distribution structures to scale its business operations. Today, the Group is looking at new opportunities to further enlarge its portfolio with product offering and services, in order to become a leading 360° platform of lifestyle consumer tech.
The Lexon award-winning products include:
Oblio :
A must-have innovation for today’s world, Oblio is a sleek UV-C sanitizer that prevents the spread of harmful bacteria found on our smartphones. Using its built-in UV-C LED technology located on its front interior, Oblio can deliver a 360° disinfection by simply flipping the phone to expose each surface for a 20-minute sanitizing cycle. Oblio’s efficiency has been proven through lab testing to kill 99.9% of viruses present on the surface of smartphones, including H1N1.
Also acting as a 10W wireless charger, Oblio can fully charge a smartphone in 3 hours. Its discrete vase-like shape makes it a beautiful design item that can be proudly displayed in a home or office, encouraging a break from your screen while your phone is being fast-charged and deeply sanitized.
Compatible with all mobile phones for sanitizing function, and all Qi-enabled smartphones such as the latest iPhone & Android devices for the wireless charging function.
MSRP: 79.90 $/€
Mino T : Made for exploring, Mino T is an outdoor speaker designed with a sleek carabiner to clip to your bag or bike. Boasting an IPX4 water resistance combined with an ultra-robust finish, it is ready to follow you in all your adventures. Carefully engineered with a passive bass system, Mino T allows you to enjoy a more balanced, fuller sound on the go with up to 5h of continuous playtime. Built with a considered design in mind, this speaker is also a stand-alone modern piece that you can proudly display indoors, on its matching stand.
MSRP: 49.90 $/€
Mina M :
With its compact size, statement-making aluminum base and water-resistant casing, the Mina M is the perfect way to inspire any space, indoor and out. Mina M brings an impressive 9 LED light color range to your bedside, workspace, or patio. The color change and dimming function are all controlled by a press down feature on the top of the light. Mina M is rechargeable using any Qi-enabled wireless charging station. You can also charge Mina M by using a USB-C charging cable. The Mina M has up to 24h of battery life from a single charge, making it the perfect companion all day and night.
MSRP: 49.90 $/€
Mino+ :
This mini portable Bluetooth® speaker fits in the palm of your hand to deliver an impressive 3W sound quality for up to 3 hours! Mino+ offers two charging methods: wirelessly with any Qi charging pad or via its USB-C port. When connected to your phone, you can use Mino+ to take selfies, start and stop recording videos, and answer calls using the bottom button.
Thanks to its built-in TWS technology, you can connect two Mino+ together and double the pleasure with an immersive stereo sound. Mino+ comes in 3 finishes (aluminum, chrome and glossy) and 24 colors to bring a stylish touch to your decor.
MSRP: 29.90 $/€
These four products have been designed in collaboration with Manuela Simonelli & Andrea Quaglio.
No connector, no cable: PowerSound is a revolutionary 2-in-1 device that combines a 5000 mAh wireless power bank with a 360° Bluetooth speaker, while charging and recharging itself entirely wirelessly. Capable of charging all Qi-enabled smartphones or earbuds, it can be recharged by setting it on top of any wireless station. Thanks to its 5W built-in Bluetooth® speaker, PowerSound allows you to enjoy an immersive sound for up to 20 hours. Easy to carry and ultra-stylish, PowerSound has a smooth design crafted from durable synthetic leather and fabric.
MSRP: 79.90 $/€
C-Pen :
The C-Pen offers a unique 2-in-1 writing and storage experience. A ballpoint pen with a 32 GB USB-C memory drive thoughtfully engineered into the pencap. 32 GB of memory means you can transfer and store up to 4000 pictures, 7000 songs, or 40 hours of video. Compatible with computers, tablets, and smartphones with a USB-C port, the C-Pen is a handy way to transfer memories or notes between all your devices. The must have accessory for the modern on-the-go person, available in 6 colors in a glossy or matt finish and working with a universal refill.
MSRP:39.90 $/€
These two products have been designed in collaboration with Alain Berteau.
About the Red Dot Award:
The Red Dot Award - Product Design, whose origins date back to 1955, appraises the best products created every year. In roughly 50 categories , manufacturers and designers can enter their innovations in the competition. According to the motto “In search of good design and innovation”, the jury evaluates the entries and only awards a Red Dot to products that win them over with their high design quality.
About Lexon:
Since its creation in 1991, Lexon has relentlessly pushed the limits and created a difference in the world of design while remaining true to its commitment to make small objects useful, beautiful, innovative and affordable. Whether in electronics, audio, travel accessories, office or leisure, Lexon has established a special relationship with creativity and partnered with the best designers around the world to create timeless collections of lifestyle products. Following its recent acquisition by BOW Group, a global player in the lifestyle and wearable consumer markets, Lexon is writing a new chapter in its history, experiencing a staggering international growth and digital expansion. Today, with 30 years of existence, more than 200 awards, collaboration with some of the most renowned designers, a retail presence in more than 90 countries across the Globe, Lexon has truly established itself as a worldly-known French design brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005520/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
